demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID 19 hospitalized
COVID 19 hospitalizedCOVID-19 mild to moderate
inhaled interferon
IFN alpha
pegylated interferon-α2b Pandit Shashi Bhushan
recombinant super-compound interferon rSIFN-co Li
SNG001 inhaled interferon beta Synairgen SG016

2 studies excluded by filtering options 0

9379 SPRINTER, 2022 110risk of bias not avaialble
9380 ACTIV-2 SNG001, 2022 110risk of bias not avaialble